FEDERAL REGISTER INDEX
January–August 2021

Withdrawal of Approval of New Drug Applications:
- Bacitracin for Injection – *14127 (Mar 12)*
- Bristol-Meyers Squibb Company, et al. – *14447 (Mar 16)*
- Fresenius Kabi USA, LLC, et al. – *40591 (Jul 28)*
- Lederle Laboratories et al. – *26058 (May 12)*
- Lederle Laboratories et al.; Correction – *31722 (Jun 15)*
- Morton Grove Pharmaceuticals Inc., et al.; Correction – *27440 (May 20)*

Withdrawal of Approval of Three New Drug Applications:
- PolyMedica Industries Inc., et al. – *12474 (Mar 3)*

Withdrawal of Drug Products from Sale for Reasons of Safety or Effectiveness:
- BELVIQ (Lorcaserin Hydrochloride) Tablets, 10 Milligrams, and BELVIQ XR (Lorcaserin Hydrochloride) Extended-Release Tablets, 20 Milligrams – *12697 (Mar 4)*

Withdrawal of Drug Products from Sale for Reasons other than Safety or Effectiveness:
- AVACLYR (Acyclovir Ophthalmic Ointment), 3 Percent – *27436 (May 20)*
- Folic Acid, Oral Tablets, 1 Milligram, and Other Drug Products – *15682 (Mar 24)*
- NIPRIDE RTU (Sodium Nitroprusside), 10 Milligrams/50 Milliliters (0.2 Milligrams/Milliliters) – *14451 (Mar 16)*
- NORMODYNE (labetalol hydrochloride) Injection, 5 Milligrams per Milliliter – *27440 (May 20)*
- NYMALIZE (nimodipine), Oral Solution, 3 Milligrams/Milliliter – *9944 (Feb 17)*

Withdrawal of Drug Products from Sale for Reasons Other Than Safety or Effectiveness:
- VOTRIENT (Pazopanib Hydrochloride) Tablets, 400 Milligrams – *42843 (Aug 5)*